Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP217411.RAm047fyJzjzJZ81zYC9unw0AzYmBhCKv1aF4Fs7rp8FY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP217411.RAm047fyJzjzJZ81zYC9unw0AzYmBhCKv1aF4Fs7rp8FY130_assertion type Assertion NP217411.RAm047fyJzjzJZ81zYC9unw0AzYmBhCKv1aF4Fs7rp8FY130_head.
- NP217411.RAm047fyJzjzJZ81zYC9unw0AzYmBhCKv1aF4Fs7rp8FY130_assertion description "[The 5-year survival rate according to the serum level of CEA in the patients with stage I NSCLC were 88.3% for the normal group and 76.3% for the high group.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP217411.RAm047fyJzjzJZ81zYC9unw0AzYmBhCKv1aF4Fs7rp8FY130_provenance.
- NP217411.RAm047fyJzjzJZ81zYC9unw0AzYmBhCKv1aF4Fs7rp8FY130_assertion evidence source_evidence_literature NP217411.RAm047fyJzjzJZ81zYC9unw0AzYmBhCKv1aF4Fs7rp8FY130_provenance.
- NP217411.RAm047fyJzjzJZ81zYC9unw0AzYmBhCKv1aF4Fs7rp8FY130_assertion SIO_000772 21397974 NP217411.RAm047fyJzjzJZ81zYC9unw0AzYmBhCKv1aF4Fs7rp8FY130_provenance.
- NP217411.RAm047fyJzjzJZ81zYC9unw0AzYmBhCKv1aF4Fs7rp8FY130_assertion wasDerivedFrom befree-20140225 NP217411.RAm047fyJzjzJZ81zYC9unw0AzYmBhCKv1aF4Fs7rp8FY130_provenance.
- NP217411.RAm047fyJzjzJZ81zYC9unw0AzYmBhCKv1aF4Fs7rp8FY130_assertion wasGeneratedBy ECO_0000203 NP217411.RAm047fyJzjzJZ81zYC9unw0AzYmBhCKv1aF4Fs7rp8FY130_provenance.